Tag Archives: Stephen Vogt

February, 2017

  • 22 February

    The 2017 Hepatitis C Treatment Landscape

    Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, particularly when it comes to direct-acting antiviral medications. This included various drug approvals and access improvements for hepatitis C medications, including Daklinza, Epclusa, Sovaldi/velpatasvir, Viekira, and Zepatier. As we make our way deeper into 2017, …

  • 15 February

    Understanding the Hepatitis C Testing Process

    Many of your patients will likely need to be screened for hepatitis C, which means that they will have many questions during the testing process. This blog geared to patient education can help your patients understand each step of what can be a stressful time in their lives. Q: Do …

  • 1 February

    Get Moving for GI Cancers

    Finding an activity that one can do regularly – whether that’s walking, playing basketball, cycling, or anything else that raises heart rates and moves big muscle groups – brings health benefits in a variety of ways. Lowering the risk of cancer is one such benefit, particularly when it comes to …

January, 2017

  • 25 January

    HCV: Relapse or Reinfection?

    Today’s hepatitis C medications offer extremely high cure rates. In fact, the few cases of a previously treated patient later testing positive for hepatitis C has some patients wondering “did I relapse or could I have been reinfected?” There are six different genotypes of the hepatitis C virus (as well …

  • 11 January

    Psoriasis and Skin Cancer

    The autoimmune skin disease called psoriasis tends to be associated with other health concerns, including diabetes, heart disease, and depression. Unfortunately, yet another disease is being added to this list: melanoma. Early research investigating the potential link between psoriasis and skin cancer were unclear as to whether the psoriasis or …

December, 2016

  • 14 December

    Let’s Screen Everyone

    Too many people infected with the hepatitis C virus (HCV) simply don’t know their disease status. As many as one in four cases of HCV infection are undiagnosed, as I pointed out in a blog earlier this year (Finding the Missing Cases), even when current federal guidelines for hepatitis C …

November, 2016

  • 30 November

    PSA: The Prostate Cancer Screening Test

    Prostate cancer is the second most common cancer in American men, following skin cancer. One in every seven men will be diagnosed with this form of cancer in his lifetime; with the average age of diagnosis being age 66. In terms of fatalities, only lung cancer comes with a higher …

  • 22 November

    HCV Research Round-up

    Hepatitis C treatment options continue to be a vibrant field full of exciting research, including the following: Genotype 3 of the hepatitis C virus (HCV) has remained harder-to-treat among the six main genotypes. New research presented at the 2016 AASLD conference now offers promising news for treating genotype 3. According …

  • 8 November

    Priced Out of the Post-Cancer Care Market

    After successful breast cancer treatment, many women are prescribed hormone therapy to reduce the risk of a cancer recurrence. This long-term medication cost can be an adherence barrier for some women and this “cost problem” appears to affect more women than previously thought. New research – based on 8,700 women …

October, 2016

  • 26 October

    Diving Deeper with Oral MS Medications

    Over the past few years, new oral medications for multiple sclerosis have gained Food and Drug Administration (FDA) approval, giving patients treatment options beyond injectable forms of medication. With multiple sclerosis (MS) medications, one of the primary goals is to extend the time between relapses, which is why these medications …